Clinical study to evaluate the efficacy and safety of TA-650 in patients with psoriasis

INTERVENTION: Intervention name : TA‐650 (Infliximab) Dosage And administration of the intervention : Intravenous drip infusion CONDITION: Psoriasis PRIMARY OUTCOME: Efficacy (clinical response), Safety and Pharmacokinetics INCLUSION CRITERIA: [Inclusion criteria] Psoriasis patients who are candidates for phototherapy or systemic therapy, 16 years and above, male and female. [Exclusion criteria] Patients who, have previously used any anti‐TNFalpha therapy, have a history of serious infection which caused hospitalization within 6 months before the registration, have an active tuberculosis, have a complication or a history of malignancy within 5 years before the registration.